The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC Sept 2021 | DESTINY-Lung01: a practice-changing trial for NSCLC
Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, shares his thoughts on the practice-changing DESTINY-Lung01 trial (NCT03505710) that demonstrated the efficacy of trastuzumab deruxtecan (T-DXd) for patients with HER2-mutant non-small cell lung cancer (NSCLC). Dr Spira underlines the importance of testing patients for this mutation to enable access to this highly promising targeted therapy. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.
